BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Rhea-AI Summary

BriaCell (Nasdaq: BCTX) will present three posters at the San Antonio Breast Cancer Symposium (SABCS) on December 10, 2025, reporting positive Phase 2 survival and Phase 3 biomarker data.

A pooled interim analysis of 116 patients with MHC subtyping in the ongoing pivotal Phase 3 showed an excellent safety profile, improved PFS in HR+/HER2- and HER2-low subtypes, and NLR as a potential biomarker. Phase 1/2 data in 54 metastatic breast cancer patients reported continued overall survival benefit and DTH as a possible predictive biomarker. Cytokine analysis of 30 patients suggests Th1-biased signatures may predict response. An interim Phase 3 analysis is expected in 1H2026.

Positive

• Pooled interim analysis includes 116 patients
• Improved PFS reported in HR+/HER2- and HER2-low subtypes
• Phase 1/2 54-patient cohort shows continued overall survival benefit
• Identification of multiple potential biomarkers: NLR, DTH, Th1 cytokines
• Interim Phase 3 analysis expected in 1H2026

Negative

• Key data are interim or maturing, not final readouts
• Small cohort sizes: 54 and 30 patients limit statistical conclusiveness
• Phase 3 results dependent on ongoing study and future interim analysis timing

Key Figures

Phase 3 interim patients 116 patients Pooled interim analysis with MHC subtyping in pivotal Phase 3

Phase 1/2 combo patients 54 metastatic breast cancer patients Bria-IMT plus anti–PD-1 CPI Phase 1/2 study

Cytokines analyzed 35 blood cytokines/chemokines Biomarker analysis after Bria-IMT regimens

Cytokine analysis patients 30 patients Phase 1/2 Bria-IMT alone or with CPI

Posters at SABCS Three poster presentations Clinical data at SABCS 2025 on Dec 10, 2025

Interim analysis timing 1H2026 Expected interim analysis of pivotal Phase 3 study

Market Reality Check

$0.3606 Last Close

Volume Volume 84,861 is 1.53x the 20-day average of 55,505, indicating elevated trading ahead of the data presentations. high

Technical Shares at 10.31 are trading below the 200-day MA of 22.04 and sit 94.59% below the 52-week high of 190.5.

Peers on Argus

While BCTX was down 7.9%, several immuno-oncology peers also traded lower: ADAP -17.57%, PRTG -10.39%, CYCC -5.84%, NXTC -3.64%, and IMNN -2.59%, suggesting broader biotech weakness but with no momentum-cluster flag.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 10	SABCS data update	Positive	-7.9%	Presented Phase 2 survival and Phase 3 biomarker data across three SABCS posters.
Dec 09	Phase 3 enrollment	Positive	-2.1%	Reported Phase 3 enrollment exceeding expectations with interim OS readout targeted for 1H2026.
Dec 02	SABCS presentation plan	Positive	+3.7%	Announced SABCS posters with Phase 2 survival benefit and Phase 3 biomarker signals.
Nov 25	Upcoming SABCS data	Positive	+13.5%	Flagged positive Phase 2/3 clinical and survival data to be highlighted at SABCS 2025.
Nov 20	AI collaboration	Positive	-0.6%	Announced AI-based small-molecule discovery collaboration via BriaPro and Receptor.AI.

Pattern Detected

Recent clinically positive headlines often saw mixed or negative price reactions; 3 of the last 5 events with favorable clinical or strategic updates had negative 24-hour moves, indicating a pattern of skepticism or profit-taking on good news.

Recent Company History

Over the past few months, BriaCell has repeatedly highlighted progress in its metastatic breast cancer programs. Updates included new Phase 3 site additions and DSMB confirmations of no safety concerns, alongside Fast Track status and multiple SABCS and ESMO biomarker presentations. Clinical-trial news has produced both sharp gains (up to 13.53%) and notable declines (down to -7.9%) within 24 hours. This announcement continues the theme of emphasizing survival and biomarker signals ahead of an interim Phase 3 analysis expected in 1H2026.

Market Pulse Summary

This announcement highlights maturing survival data and multiple biomarker readouts that aim to refine patient selection for Bria-IMT-based regimens in metastatic breast cancer. Interim Phase 3 analysis is expected in 1H2026, following prior DSMB reviews and site expansion. Investors may track future updates on overall survival, safety, and validation of markers such as NLR, DTH, and Th1-biased cytokine signatures, alongside any new regulatory filings or capital-related disclosures from the company.

Key Terms

progression-free-survival (PFS) medical

"demonstrated an excellent safety profile, improved progression-free-survival (PFS) n HR+/HER-2"

Progression-free survival (PFS) is the length of time during and after a treatment that a patient’s disease does not get worse, measured from the start of therapy until disease progression or death. Investors watch PFS because it’s a common clinical-trial endpoint that signals whether a drug delays worsening of a condition; stronger PFS results can speed approvals, boost sales prospects, and change a drug’s perceived value—like how long a car runs before needing major repairs.

neutrophil to lymphocyte ratio (NLR) medical

"potential use of Neutrophil to Lymphocyte Ratio (NLR) as a biomarker of clinical benefit"

The neutrophil to lymphocyte ratio (NLR) is a simple blood test metric that compares the number of neutrophils (white blood cells that often rise with acute inflammation or infection) to lymphocytes (white blood cells tied to longer-term immune response). Investors watch NLR because it serves as a general marker of systemic inflammation or immune status that can influence patient outcomes, enrollment or endpoints in clinical trials, and the commercial prospects of therapies — think of it as a quick health check that can sway a drug’s risk and reward profile.

delayed type hypersensitivity (DTH) medical

"potential use of delayed type hypersensitivity (DTH) as a biomarker predictive of clinical benefit"

An immune reaction that appears hours to days after exposure to a substance, driven by white blood cells that coordinate a focused inflammatory response rather than immediate allergy-type symptoms. Think of it like a slow-burning alarm that recruits cleanup crews to the site; in drug and vaccine development it signals whether a treatment engages the immune system, and it can affect safety, efficacy, dosing and regulatory outcomes—key factors for investors assessing clinical progress and risk.

cytokines/chemokines medical

"Analysis of 35 different blood cytokines/chemokines from 30 patients enrolled"

Cytokines and chemokines are small proteins the body’s cells use to send signals that control immunity and inflammation; cytokines are broader messengers while chemokines are a subset that guide cells to specific locations. For investors, their levels and behavior are important because they serve as measurable indicators of how well drugs or vaccines work and whether treatments cause harmful inflammation, making them key biomarkers and drug targets in biotech and pharmaceutical valuations.

immune checkpoint inhibitor (CPI) medical

"Bria-IMT alone or in combination with an immune checkpoint inhibitor (CPI) suggests"

An immune checkpoint inhibitor (CPI) is a type of drug that lifts molecular “brakes” that normally keep the immune system from attacking the body, allowing immune cells to recognize and destroy cancer cells; think of it as unlocking a gate so the immune system can do its job. Investors care because CPIs can produce long-lasting benefits for some patients, drive high drug sales, face specific regulatory and trial risks, and often command premium pricing, making them a major commercial and clinical development focus in oncology.

AI-generated analysis. Not financial advice.

• Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key biomarker data from the pivotal Phase 3 
• The pivotal Phase 3 study of Bria-IMT+CPI in advanced metastatic breast cancer is ongoing with an interim analysis expected in 1H2026

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, will be presenting positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS^®) taking place December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, Texas.

“Our survival and biomarker data at SABCS is very encouraging because it underscores the potential of our novel immunotherapy and precision medicine to treat cancer patients,” stated William V. Williams, MD, BriaCell’s President & CEO. “We remain committed to improve survival and clinical outcomes in cancer patients whose medical needs remain unmet.”

“We are extremely pleased with biomarker and patient subgroup data suggesting their use for identifying patients who are most likely to benefit from our treatment,” stated Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer.

The details of the poster presentations are listed below.

Late-Breaking Abstract Number: 3688
Presentation Number: PS1-13-22
Presentation Title: Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial
Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM - 2:00 PM

A pooled interim analysis of 116 patients with available MHC subtyping in the ongoing pivotal phase III study demonstrated an excellent safety profile, improved progression-free-survival (PFS) n HR+/HER-2 and HER2- low subtypes and potential use of Neutrophil to Lymphocyte Ratio (NLR) as a biomarker of clinical benefit,

Late-Breaking Abstract Number: 3713
Presentation Number: PS1-13-23
Presentation Title: Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM - 2:00 PM

Maturing data analysis of the of the Phase 1/2 study evaluating the Bria-IMT regimen in combination with an anti–PD-1 checkpoint inhibitor (CPI) in 54 metastatic breast cancer demonstrated continued overall survival benefit with potential use of delayed type hypersensitivity (DTH) as a biomarker predictive of clinical benefit.

Abstract Number: 1614
Presentation Number: PS2-09-03
Presentation Title: Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer.
Poster Presentation Date/Time: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM

Analysis of 35 different blood cytokines/chemokines from 30 patients enrolled in the Phase 1/2 studies of Bria-IMT alone or in combination with an immune checkpoint inhibitor (CPI) suggests that Th1 biased cytokines and chemokines may serve as potential predictive biomarkers of clinical responses to the Bria-IMT regimen in metastatic breast cancer

Copies of the posters will be made available at https://briacell.com/scientific-publications/.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about presenting three posters at the 2025 SABCS, and the contents of such posters, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com

FAQ

What Phase 3 data will BriaCell (BCTX) present at SABCS 2025 and when?

BriaCell will present pooled Phase 3 biomarker and safety data from 116 patients on December 10, 2025.

What Phase 2 survival results did BriaCell (BCTX) report at SABCS 2025?

Maturing Phase 1/2 data in 54 metastatic breast cancer patients show continued overall survival benefit; presented December 10, 2025.

Which biomarkers did BriaCell (BCTX) identify as potentially predictive at SABCS 2025?

Reported candidate biomarkers include NLR, delayed type hypersensitivity (DTH), and Th1-biased cytokine signatures.

When is the BriaCell (BCTX) Phase 3 interim analysis expected?

An interim analysis for the pivotal Phase 3 study is expected in 1H2026.

Where can investors access BriaCell (BCTX) SABCS posters?

Copies of the posters will be available on BriaCell's scientific publications page at https://briacell.com/scientific-publications/.